Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesDurable Medical Equipment (DME)SummaCare CPAP Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Continuous Positive Airway Pressure (CPAP) for Obstructive Sleep Apnea

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity criteria for CPAP and related positive airway pressure equipment for commercial and Medicare members with obstructive sleep apnea, including diagnostic testing, initial and continued therapy, Medicare limitations, coding, and non-covered uses.

    Policy Summary
    PayerSummaCare
    PolicyContinuous Positive Airway Pressure (CPAP) for Obstructive Sleep Apnea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAugust 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionDocument a positive qualifying sleep study, applicable AHI/RDI criteria, and objective adherence and clinical benefit for continued therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AHI/RDI ≥15Primary qualifying threshold
    12 weeksMedicare initial coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥4 hours/nightContinued-use adherence
    ≥30 eventsCommercial high-threshold minimum
    InvestigationalOther indications
    Commercial + MedicarePopulations addressed

    CPAP Coverage Criteria

    Commercial Initial CPAP Authorization

    Covered for commercial members when ALL of the following are met:

    ALL of the following

    • A qualifying sleep study

      • Positive facility-based nocturnal polysomnogram (NPSG).
      • Positive home sleep test using a Type II, Type III, Type IV(A), or Watch-PAT device.
    • ONE of the following clinical criteria

      • AHI or RDI is at least 15 events per hour, with a minimum of 30 events.
      • AHI or RDI is 5 to less than 15 events per hour

        • AHI or RDI is at least 5 and less than 15 events per hour, with a minimum of 10 events.
        • At least ONE associated condition or symptom

          • Documented history of stroke.
          • Documented hypertension resistant to 3 or more medications.
          • Documented ischemic heart disease.
          • Documented impaired cognition, mood disorder, or insomnia.
          • Excessive daytime sleepiness documented by an Epworth score greater than 10.
          • More than 20 episodes of oxygen desaturation below 85% during a full-night sleep study, or any one episode of oxygen desaturation below 70%.

    Continuation Therapy

    Continued use beyond the initial authorization period is medically necessary when ALL of the following are documented:

    ALL of the following

    • Face-to-face clinical reevaluation by the treating physician documents that symptoms of obstructive sleep apnea have improved.
    • Objective evidence of adherence to positive airway pressure therapy is reviewed by the treating physician.

      Adherence means use of positive airway pressure for 4 or more hours per night on at least 70% of nights during a consecutive 30-day period at any time during the initial period of usage.

    Medicare Initial 12-Week Coverage

    For adult Medicare beneficiaries with OSA, CPAP is initially covered for 12 weeks when ALL applicable requirements are met:

    ALL of the following

    • The provider educates the beneficiary before CPAP use regarding proper operation of the device.

      A caregiver, such as a family member, may provide the education and assistance if consistently available in the beneficiary's home and willing and able to safely operate the device.

    • A clinical evaluation and positive sleep test establish the diagnosis of OSA.
    • A qualifying sleep test

      • Attended polysomnography (PSG) performed in a sleep laboratory.
      • Unattended home sleep test (HST) using a Type II device.

    Medicare Coverage With Evidence Development

    Medicare provides limited coverage with evidence development (CED) for adult beneficiaries who do not qualify under the standard criteria above when ALL of the following are met:

    ALL of the following

    • The clinical study addresses at least ONE of the following questions

      • In Medicare-aged subjects with clinically identified OSA risk factors, how does the diagnostic accuracy of a clinical trial of CPAP compare with PSG and Type II, III, and IV HST in identifying subjects with OSA who will respond to CPAP?
      • In Medicare-aged subjects with clinically identified OSA risk factors who have not undergone confirmatory PSG or Type II, III, or IV HST, does CPAP cause clinically meaningful harm?
    • The principal purpose of the research study is to test whether a particular intervention potentially improves participants' health outcomes.
    • The study is well supported by available scientific and medical information or is intended to clarify or establish health outcomes of interventions already in common clinical use.

    For the diagnosis of obstructive sleep apnea, diagnostic tests other than the qualifying facility-based PSG/NPSG or Type II, III, or IV home sleep tests specified in this policy are not sufficient for coverage of CPAP.

    SummaCare considers CPAP experimental and investigational for all indications other than those covered under this policy's obstructive sleep apnea criteria.

    CPAP is not covered for indications outside the covered obstructive sleep apnea criteria and is considered experimental and investigational for those uses.

    Coding and Qualification Thresholds

    Covered HCPCS CodesHCPCSCovered
    E0470-E0471Respiratory assist device, bi-level pressure capability, without back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask
    A4604Tubing with integrated heating element for use with positive airway pressure device
    A7027Combination oral/nasal mask, used with continuous positive airway pressure device
    A7028Oral cushion for combination oral/nasal mask, replacement only, each
    A7029Nasal pillows for combination oral/nasal mask, replacement only, pair
    A7030Full face mask used with positive airway pressure device, each
    A7031Face mask interface, replacement for full face mask, each
    A7032Cushion for use on nasal mask interface, replacement only, each
    A7033Pillow for use on nasal cannula type interface, replacement only, pair
    A7034Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap
    1–10 of 18
    1/2
    Commercial AHI/RDI high threshold
    PopulationCommercial members
    MeasureApnea-hypopnea index (AHI) or respiratory disturbance index (RDI)
    Qualifying thresholdAt least 15 events per hour, with a minimum of 30 events
    AHI/RDI moderate threshold
    Commercial moderate rangeAHI or RDI at least 5 and less than 15 events per hour
    Medicare moderate rangeAHI or RDI at least 5 and no more than 14 events per hour
    Additional requirement

    Provider Requirements and Denial Risks

    Documentation Required

    Document Clinical Qualification and Continued Benefit

    For commercial members, CPAP with pressure relief technology, APAP, and APAP with pressure relief technology are medically necessary when supported by a positive facility-based NPSG or qualifying home sleep test and the applicable clinical criteria. Continued coverage beyond the initial authorization period requires documented clinical benefit and objective adherence.

    • AHI or RDI ≥15 events/hour, with a minimum of 30 events; or
    • AHI or RDI ≥5 and <15 events/hour, with a minimum of 10 events, plus at least one qualifying condition: documented stroke; resistant hypertension treated with 3 or more medications; ischemic heart disease; impaired cognition, mood disorder, or insomnia; excessive daytime sleepiness documented by Epworth score >10; qualifying oxygen desaturation; or obesity with BMI >30 and neck circumference >17 inches for men or >16 inches for women.
    • Beyond the initial authorization period, the treating physician must document a face-to-face reevaluation showing improved OSA symptoms and review objective adherence evidence.
    • Adherence requires use for ≥4 hours per night on at least 70% of nights during a consecutive 30-day period at any time during the initial usage period.
    Documentation Required

    Therapy Overview

    Continuous positive airway pressure (CPAP) is a non-invasive therapy that delivers a single level of air pressure through a nasal or similar interface during sleep to help prevent collapse of the upper airway.

    Key Definitions

    Apnea-hypopnea index (AHI)
    TermApnea-hypopnea index (AHI)
    What it countsEpisodes of apnea and hypopnea
    DefinitionThe average number of apnea and hypopnea episodes per hour
    Respiratory disturbance index (RDI)
    TermRespiratory disturbance index (RDI)
    What it measuresRespiratory disturbances
    DefinitionThe average number of respiratory disturbances per hour

    Positive Airway Pressure Equipment

    Positive Airway Pressure Equipment

    Positive airway pressure equipment is medically necessary when the applicable commercial or Medicare obstructive sleep apnea criteria are met and, for continued therapy, clinical benefit and adherence are documented.

    DME medical necessity: Provide positive airway pressure equipment for obstructive sleep apnea when supported by an accepted qualifying sleep study and the applicable commercial or Medicare AHI/RDI criteria. For continued use beyond the initial authorization period, the treating physician must document improved obstructive sleep apnea symptoms and review objective adherence.Commercial or Medicare criteria as applicable

    Applicable equipment includes CPAP, pressure-relief CPAP, autoPAP, pressure-relief autoPAP, and related masks, interfaces, tubing, filters, chinstraps, headgear, humidifier water chambers, and exhalation ports.

    Required Documentation

    Documentation Required

    Document medical necessity for initial and continued therapy

    The record must include a positive qualifying sleep study, applicable AHI/RDI results and clinical criteria, a face-to-face reevaluation documenting improved obstructive sleep apnea symptoms, and objective adherence reviewed by the treating physician for continued use.

    • Qualifying studies include a facility-based NPSG or Type II, III, IV(A), or Watch-PAT home sleep test for commercial authorization.
    • For continued therapy, the treating physician must document clinical benefit and review objective adherence.
    Documentation Required

    Document Medicare testing oversight and CPAP education

    For Medicare beneficiaries, document treating-physician ordering and appropriate physician supervision of the sleep test, as well as beneficiary education in proper CPAP use before device initiation.

    • The positive diagnosis must include a clinical evaluation and an attended PSG or qualifying unattended Type II, Type III, or Type IV home sleep test.
    • A Type IV device must measure at least 3 channels.

    Non-Covered Uses

    Not covered: CPAP is not covered when it is prescribed for indications other than the covered obstructive sleep apnea criteria or when coverage is supported only by diagnostic tests that do not meet the policy's qualifying testing requirements. Such use is considered experimental and investigational.

    Policy Summary
    PayerSummaCare
    PolicyContinuous Positive Airway Pressure (CPAP) for Obstructive Sleep Apnea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAugust 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionDocument a positive qualifying sleep study, applicable AHI/RDI criteria, and objective adherence and clinical benefit for continued therapy.
    SourceLink
    On This Page
    CPAP Coverage CriteriaCoding and Qualification ThresholdsProvider Requirements and Denial RisksTherapy OverviewKey DefinitionsPositive Airway Pressure EquipmentRequired DocumentationNon-Covered Uses
    Obesity with BMI greater than 30 and neck circumference greater than 17 inches for men or 16 inches for women.
    Unattended HST using a Type III device.
  1. Unattended HST using a Type IV device that measures at least 3 channels.
  2. The sleep test was previously ordered by the beneficiary's treating physician and furnished under appropriate physician supervision.
  3. ONE AHI/RDI criterion

    • AHI or RDI is at least 15 events per hour.
    • AHI or RDI is 5 through 14 events per hour

      • AHI or RDI is at least 5 and less than or equal to 14 events per hour.
      • At least ONE documented symptom or condition

        • Excessive daytime sleepiness.
        • Impaired cognition, mood disorder, or insomnia.
        • Hypertension.
        • Ischemic heart disease.
        • History of stroke.
  4. AHI or RDI is calculated as the average number of events per hour. If calculated from less than 2 hours of continuous recorded sleep, the total recorded events must be at least the number that would have been required during a 2-hour period.
  5. Apnea is cessation of airflow for at least 10 seconds. Hypopnea is an abnormal respiratory event lasting at least 10 seconds, with at least a 30% reduction in thoracoabdominal movement or airflow from baseline and at least 4% oxygen desaturation.
  6. After the initial 12-week period, CPAP continues to be covered only for beneficiaries diagnosed with OSA who benefit from CPAP during that period.
  7. The study does not unjustifiably duplicate existing studies.
  8. The study design is appropriate to answer the research question.
  9. The study is sponsored by an organization or individual capable of executing it successfully.
  10. The study complies with applicable Federal regulations protecting human subjects under 45 CFR Part 46 and, if FDA-regulated, 21 CFR Parts 50 and 56.
  11. All aspects of the study are conducted according to appropriate standards of scientific integrity.
  12. The study has a written protocol that clearly addresses or incorporates by reference the Medicare standards.
  13. The study is not designed exclusively to test toxicity or disease pathophysiology in healthy individuals. Trials measuring therapeutic outcomes meet this standard only when the disease or condition is life-threatening under 21 CFR § 312.81(a) and the patient has no other viable treatment options.
  14. The study is registered on ClinicalTrials.gov by the principal sponsor or investigator before enrollment of the first subject.
  15. The protocol specifies the method and timing for public release of all prespecified outcomes, including negative or early-terminated results. Results must be public within 24 months after data collection ends; if an abstract is initially released for planned peer-reviewed publication, a full report must be public no later than 3 years after data collection ends.
  16. The protocol explicitly discusses treatment-affected subpopulations, particularly traditionally underrepresented groups; the effects of inclusion and exclusion criteria on enrollment; and plans for retention and reporting. If criteria may negatively affect recruitment or retention of underrepresented groups, the protocol explains why they are necessary.
  17. The protocol explicitly discusses whether and how results are expected to generalize to the Medicare population, including populations eligible by age, disability, or Medicaid eligibility.
  18. For moderate-range results, the applicable symptoms or comorbidities must also be documented
    Commercial moderate-threshold minimum events
    PopulationCommercial members
    Applicable rangeAHI or RDI at least 5 and less than 15 events per hour
    Minimum eventsAt least 10 events
    Excessive daytime sleepiness
    Qualifying symptomExcessive daytime sleepiness
    MeasurementEpworth Sleepiness Scale score
    ThresholdGreater than 10
    Oxygen desaturation
    Full-night study criterionMore than 20 episodes with oxygen saturation below 85% during a full-night sleep study
    Single-episode criterionAny one episode with oxygen saturation below 70%
    Clinical useQualifying oxygen desaturation may support the moderate AHI/RDI pathway
    Obesity and neck circumference
    Body mass indexBMI greater than 30
    Neck circumference—menGreater than 17 inches
    Neck circumference—womenGreater than 16 inches
    Adherence
    Nightly useAt least 4 hours per night
    FrequencyAt least 70% of nights
    Review periodA consecutive 30-day period anytime during the initial usage period
    Qualifying sleep study and medical necessity
    Accepted facility-based testPositive attended polysomnography (PSG) or facility-based NPSG performed in a sleep laboratory
    Accepted home testsPositive Type II, Type III, Type IV(A), or Watch-PAT home sleep test; a Type IV device must measure at least 3 channels
    Medical-necessity documentationThe applicable AHI/RDI criteria must be met, and continued therapy requires documented clinical benefit and objective adherence
    Medicare testing oversightThe test must be ordered by the treating physician and furnished under appropriate physician supervision

    Meet Medicare Ordering, Supervision, and Education Requirements

    For Medicare CPAP coverage, the treating physician must order the sleep test before it is performed, ensure it is furnished under appropriate physician supervision, and ensure the beneficiary is educated in proper device use before CPAP begins. A consistently available, willing, and able caregiver may provide the education or operate the device when appropriate.

    • Qualifying testing includes attended laboratory PSG or unattended Type II, Type III, or Type IV HST measuring at least 3 channels.
    • Medicare initially limits CPAP coverage to 12 weeks; continued coverage requires documentation that the beneficiary benefits from CPAP during that period.
    • The positive OSA diagnosis must include a clinical evaluation and a qualifying positive sleep test.
    Denial Risk

    Avoid Unqualifying Diagnostic Tests or Indications

    CPAP coverage is at denial risk when OSA is established using a diagnostic test other than the qualifying tests recognized for CPAP coverage, or when CPAP is prescribed for an indication outside the policy criteria. Other diagnostic tests are not sufficient to support CPAP coverage, and SummaCare considers CPAP experimental and investigational for all other indications.

    • Use only an attended PSG or qualifying unattended Type II, Type III, or Type IV HST with at least 3 channels for Medicare CPAP coverage.
    • A non-qualifying diagnostic test does not establish the required positive OSA diagnosis for CPAP coverage.
    • An indication that does not meet the policy's AHI/RDI thresholds and required symptoms or comorbidities is not covered.
    Denial Risk

    Prevent Medical-Necessity and Continuation Denials

    Claims may be denied when the member does not meet the applicable AHI/RDI threshold, required event count, qualifying symptom or comorbidity criteria, or documentation requirements. For Medicare, initial coverage is limited to 12 weeks and continued coverage requires documented benefit during that period; for commercial members, continued use requires documented symptom improvement and objective adherence.

    • Commercial qualification requires either AHI/RDI ≥15 with at least 30 events, or AHI/RDI ≥5 and <15 with at least 10 events plus a qualifying symptom, comorbidity, desaturation finding, or obesity/neck-circumference criterion.
    • Medicare initial qualification requires AHI/RDI ≥15, or AHI/RDI ≥5 and ≤14 with documented excessive daytime sleepiness, impaired cognition, mood disorder, insomnia, hypertension, ischemic heart disease, or history of stroke.
    • Document the treating physician's clinical reevaluation, improvement or benefit, and objective adherence before requesting continued coverage.
    • Commercial adherence requires ≥4 hours per night on at least 70% of nights during a consecutive 30-day period; Medicare continuation requires evidence that the beneficiary benefited from CPAP during the initial 12-week period.
    Apnea
    EventApnea
    AirflowCessation of airflow
    Minimum durationAt least 10 seconds
    Hypopnea
    EventHypopnea
    DurationAn abnormal respiratory event lasting at least 10 seconds
    Movement or airflow reductionAt least a 30% reduction in thoracoabdominal movement or airflow compared with baseline
    Oxygen criterionAt least 4% oxygen desaturation
    Qualifying sleep study
    Facility-based modalityPolysomnography (PSG) performed in a facility-based sleep-study laboratory
    Home modalityType II or Type III home sleep test monitor
    Type IV requirementType IV home sleep test monitor measuring at least 3 channels
    MeasurementAHI and/or RDI may be measured by these qualifying sleep-study modalities